-
Annales de Dermatologie Et de... Mar 2014
Topics: Dysgeusia; Food Hypersensitivity; Food, Organic; Humans; Hypesthesia; Male; Middle Aged; Nuts; Pharyngeal Diseases; Remission, Spontaneous
PubMed: 24635959
DOI: 10.1016/j.annder.2014.01.006 -
Infection Apr 2021
Topics: Adult; Anosmia; COVID-19; COVID-19 Nucleic Acid Testing; Dysgeusia; Female; Humans; Male; Middle Aged; Outpatients; SARS-CoV-2; Sensitivity and Specificity
PubMed: 32410112
DOI: 10.1007/s15010-020-01442-3 -
Drug and Chemical Toxicology Jan 2012
Topics: Adult; Anthelmintics; Dysgeusia; Echinococcosis; Female; Humans; Middle Aged; Praziquantel
PubMed: 21830878
DOI: 10.3109/01480545.2011.584065 -
Otolaryngology--head and Neck Surgery :... Sep 1999
Topics: Adult; Dysgeusia; Electrocoagulation; Female; Humans; Tonsillectomy
PubMed: 10471880
DOI: 10.1016/S0194-5998(99)70200-7 -
Supportive Care in Cancer : Official... Mar 2022To evaluate the effectiveness of photobiomodulation (PBMT) in preventing dysgeusia in breast cancer patients treated with doxorubicin-cyclophosphamide (AC). (Randomized Controlled Trial)
Randomized Controlled Trial
Photobiomodulation therapy prevents dysgeusia chemotherapy induced in breast cancer women treated with doxorubicin plus cyclophosphamide: a triple-blinded, randomized, placebo-controlled clinical trial.
PURPOSE
To evaluate the effectiveness of photobiomodulation (PBMT) in preventing dysgeusia in breast cancer patients treated with doxorubicin-cyclophosphamide (AC).
METHODS
This is a phase II, randomized, triple-blind, placebo-controlled clinical trial involving 112 breast cancer patients treated with AC. The patients were divided equally into two groups: a test group treated with 2 J red laser and 3 J infrared laser on 21 points that were symmetrically distributed on the tongue on day 0 of four cycles of AC, and an equal placebo group treated with simulated PBMT to blind the patient, evaluator, and statistician. The clinicopathological and sociodemographic data, results of taste test, and subjective taste analysis, and the QoL, ECOG performance status, body mass index, and other side effects were recorded. The data were analyzed using ANOVA-RM/Bonferroni, Friedman/Dunn, and chi-square/Fisher's exact tests.
RESULTS
PBMT patients showed less objective and subjective taste loss (p<0.05). On the other hand, the placebo group showed a higher ECOG status (p=0.037) and more significant weight loss (p<0.001) after four cycles of AC. The QoL was significantly higher in the PBMT group (p<0.05) at all assessment periods, and PBMT treatment also reduced the incidence of cachexia (p=0.020), anorexia (p<0.001), diarrhea (p=0.040), oral mucositis (p=0.020), and vomiting (p=0.008).
CONCLUSION
PBMT reduced the taste loss and improved the overall health status and QoL of patients with breast cancer treated with AC.
TRIAL REGISTRATION
Brazilian Clinical Trials Registry ( www.ensaiosclinicos.gov.br ) approval number RBR-9qnm34y, registered on 01/05/2021.
Topics: Antineoplastic Agents; Breast Neoplasms; Cyclophosphamide; Doxorubicin; Dysgeusia; Female; Humans; Low-Level Light Therapy; Quality of Life
PubMed: 34799776
DOI: 10.1007/s00520-021-06642-7 -
Laryngo- Rhino- Otologie Aug 2021
Topics: Dysgeusia; Humans; Quality of Life; Smoking
PubMed: 34320671
DOI: 10.1055/a-1499-5488 -
European Review For Medical and... Sep 2022Zinc insufficiency has been proposed to play a role in taste and smell impairment in Coronavirus disease 2019 (COVID-19) patients. Therefore, this study aimed at...
OBJECTIVE
Zinc insufficiency has been proposed to play a role in taste and smell impairment in Coronavirus disease 2019 (COVID-19) patients. Therefore, this study aimed at comparing salivary zinc levels in COVID-19 patients with and without dysgeusia.
PATIENTS AND METHODS
A total of 127 participants were recruited for this study. The patients were divided into three groups based on their COVID-19 test results and taste impairment. Groups I and II were COVID-19 positive with and without taste loss, respectively. Group III included the negative control participants. Salivary zinc levels were measured at baseline in all groups and three months after baseline in groups I and II. Wilcoxon signed-rank test was used to compare the zinc levels between baseline and three months after baseline within each group. Mann-Whitney U test was used to compare zinc levels between groups with different degrees of taste loss.
RESULTS
Salivary zinc levels were significantly lower in the COVID-19 positive group with taste loss compared to levels in the group without taste loss or the negative controls (p<0.005). Three months after baseline, salivary zinc levels were significantly elevated in both COVID-19 positive groups (p<0.001).
CONCLUSIONS
COVID-19 patients with dysgeusia had significantly lower levels of salivary zinc than positive and negative controls. Zinc levels were elevated after recovery, which may indicate that salivary zinc is directly associated with taste abnormalities and COVID-19 outcomes. This study showed that taste impairment is associated with lower salivary zinc levels in COVID-19 patients.
Topics: Ageusia; COVID-19; Dysgeusia; Humans; Olfaction Disorders; Zinc
PubMed: 36196740
DOI: 10.26355/eurrev_202209_29793 -
CJEM Sep 2020To slow down the transmission of coronavirus disease 2019 (COVID-19), it is important to identify specific symptoms for effective screening. While anosmia/hyposmia and...
OBJECTIVES
To slow down the transmission of coronavirus disease 2019 (COVID-19), it is important to identify specific symptoms for effective screening. While anosmia/hyposmia and dysgeusia/ageusia have been identified as highly prevalent symptoms, there are wide geographic variations, necessitating the regional evaluation of the prevalence of the symptoms.
METHODS
A cross-sectional study was performed to evaluate the self-reported symptoms among adults (over 18 years old) who underwent COVID-19 tests at an ambulatory assessment centre. We identified 1,345 patients (102 positive and 1,243 negative) who visited the assessment centre between March 16 and April 15, 2020. We randomly sampled negative patients in a 1:3 ratio. The primary outcome was the prevalence of self-reported anosmia/hyposmia and dysgeusia/ageusia. Logistic regression was performed to evaluate the association between COVID-19 positivity and loss of smell and taste.
RESULTS
Fifty-six of 102 (50%) positive patients and 72 of 306 (23.5%) negative patients completed the survey. Anosmia/hyposmia and dysgeusia/ageusia were more prevalent among COVID-19 positive patients (41.1% v. 4.2%, p < 0.001 for smell and 46.4% v. 5.6%, p < 0.001 for taste). Anosmia/hyposmia and dysgeusia/ageusia were independently highly associated with COVID-19 positivity (adjusted odds ratios 14.4 and 11.4 for smell and taste, respectively).
CONCLUSION
In this Canadian study, smell and taste loss may be key symptoms of COVID-19. This evidence can be helpful in the clinical diagnosis of COVID-19, particularly settings of limited testing capacity.
Topics: Adult; COVID-19; COVID-19 Testing; Canada; Clinical Laboratory Techniques; Coronavirus Infections; Cross-Sectional Studies; Dysgeusia; Female; Humans; Incidence; Male; Middle Aged; Olfaction Disorders; Pandemics; Pneumonia, Viral; Reference Values; Risk Assessment; Self Report; Sensitivity and Specificity
PubMed: 32507123
DOI: 10.1017/cem.2020.420 -
Supportive Care in Cancer : Official... Nov 2018We analyzed the prevalence of gustatory test abnormalities in breast cancer (BC) patients undergoing chemotherapy.
PURPOSE
We analyzed the prevalence of gustatory test abnormalities in breast cancer (BC) patients undergoing chemotherapy.
METHODS
We enrolled 43 BC patients undergoing chemotherapy and 38 BC patients who had never undergone chemotherapy (control group). Two gustatory tests were conducted: an instillation method examining the threshold for four basic taste stimuli and an electrogustometry method measuring the threshold for perception with electric stimulation at the front two-thirds of the tongue (cranial nerve VII) and at the back third of the tongue (cranial nerve IX). The results of the two gustatory tests and clinicopathological factors were compared between the chemotherapy and control groups and between patients with and without awareness of dysgeusia in the chemotherapy group.
RESULTS
In the chemotherapy group, 19 (44%) patients were aware of dysgeusia and 8 (19%) had hypogeusia using the instillation method. Although more patients had parageusia in the chemotherapy than control group, no significant differences in the results of the two gustatory tests were observed. Patients with dysgeusia awareness had a higher threshold at cranial nerve IX using the electrogustometry method than those without dysgeusia awareness; no significant differences in hypogeusia were observed using the instillation method. In fact, 74% (14/19) of patients with dysgeusia awareness could identify the four tastes accurately using the instillation method. Similar results were observed for the instillation and electrogustometry methods at cranial nerve VII.
CONCLUSIONS
While approximately half of the chemotherapy patients were aware of dysgeusia, 81% (35/43) of them could accurately identify the four basic tastes using the instillation method.
Topics: Aged; Antineoplastic Combined Chemotherapy Protocols; Awareness; Breast Neoplasms; Case-Control Studies; Dysgeusia; Electrodiagnosis; Female; Humans; Middle Aged; Prevalence; Taste; Taste Threshold; Tongue
PubMed: 29754211
DOI: 10.1007/s00520-018-4256-4 -
British Dental Journal May 2011
Topics: Dysgeusia; Humans; Male; Nuts; Pinus
PubMed: 21566589
DOI: 10.1038/sj.bdj.2011.349